Do you recommend frontline bevacizumab with carbo/taxol in patients with advanced epithelial ovarian and BRCA mutation who will be receiving olaparib maintenance?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at William C Waterfield MD
I don't see an issue with using Bev and olaparib i...
Medical Oncologist at Harvard Medical School
In response to @William C. Waterfield's comment, I...
Sign in or Register to read more